Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | WNT3A | P56704 | 2/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.46 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | QPCT | Q16769 | 1/20 | 0.44 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL5070094 | 1.00 | KDM4E (0.51) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL158526 | 0.94 | SMN1; SMN2 (0.54) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL9028632 | 0.92 | SMN1; SMN2 (0.49) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL10531809 | 0.92 | KDM4E (0.49) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL16516335 | 0.90 | SMN1; SMN2 (0.57) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL8901469 | 0.90 | SMN1; SMN2 (0.57) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL2334176 | 0.90 | PRKCI (0.50) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL11810774 | 0.89 | KDM4E (0.46) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Terephthalamide SCHEMBL29216571 | 0.89 | PARP1 (0.54) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 | |
| Benzimidazole SCHEMBL4306997 | 0.89 | CTNNB1 (0.47) | KDM4EPARP1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| EP-1581217-A4 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | disclosed |
| EP-1581217-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004041277-A1 | CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | KDM4E 825/4885PARP1 77/4885SMN1; SMN2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.